Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Fludarabine
Related studies linked through entity extraction aliases.
Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
- Status
- TERMINATED
- Phase
- PHASE1
Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
- Status
- COMPLETED
- Phase
- PHASE2
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
- Status
- TERMINATED
- Phase
- NA
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
- Status
- COMPLETED
- Phase
- PHASE3
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE3
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
- Status
- COMPLETED
- Phase
- PHASE3
MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning
- Status
- COMPLETED
- Phase
- PHASE2
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
- Status
- TERMINATED
- Phase
- PHASE3
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
- Status
- TERMINATED
- Phase
- PHASE1
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Non-Myeloablative Allogeneic Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- NA
CFAR Study in Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2